356 related articles for article (PubMed ID: 18250984)
41. [CT/PET image registration based on a region similarity measure].
Yi CL; Du MH
Zhongguo Yi Liao Qi Xie Za Zhi; 2005 Jan; 29(1):7-10, 12. PubMed ID: 15875683
[TBL] [Abstract][Full Text] [Related]
42. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes.
van Baardwijk A; Bosmans G; Boersma L; Buijsen J; Wanders S; Hochstenbag M; van Suylen RJ; Dekker A; Dehing-Oberije C; Houben R; Bentzen SM; van Kroonenburgh M; Lambin P; De Ruysscher D
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):771-8. PubMed ID: 17398018
[TBL] [Abstract][Full Text] [Related]
43. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
[TBL] [Abstract][Full Text] [Related]
44. Investigation of time-of-flight benefit for fully 3-D PET.
Surti S; Karp JS; Popescu LM; Daube-Witherspoon ME; Werner M
IEEE Trans Med Imaging; 2006 May; 25(5):529-38. PubMed ID: 16689258
[TBL] [Abstract][Full Text] [Related]
45. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
[TBL] [Abstract][Full Text] [Related]
46. Limitations of CT during PET/CT.
Gollub MJ; Hong R; Sarasohn DM; Akhurst T
J Nucl Med; 2007 Oct; 48(10):1583-91. PubMed ID: 17873133
[TBL] [Abstract][Full Text] [Related]
47. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
48. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
[TBL] [Abstract][Full Text] [Related]
49. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET.
Hickeson M; Yun M; Matthies A; Zhuang H; Adam LE; Lacorte L; Alavi A
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1639-47. PubMed ID: 12458399
[TBL] [Abstract][Full Text] [Related]
50. Correlations between 18F-FDG uptake by bone marrow and hematological parameters: measurements by PET/CT.
Murata Y; Kubota K; Yukihiro M; Ito K; Watanabe H; Shibuya H
Nucl Med Biol; 2006 Nov; 33(8):999-1004. PubMed ID: 17127173
[TBL] [Abstract][Full Text] [Related]
51. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
Conrad GR; Sinha P
Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
[TBL] [Abstract][Full Text] [Related]
52. Use of the CT component of PET-CT to improve PET-MR registration: demonstration in soft-tissue sarcoma.
Somer EJ; Benatar NA; O'Doherty MJ; Smith MA; Marsden PK
Phys Med Biol; 2007 Dec; 52(23):6991-7006. PubMed ID: 18029989
[TBL] [Abstract][Full Text] [Related]
53. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
[TBL] [Abstract][Full Text] [Related]
54. Value of
Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
[TBL] [Abstract][Full Text] [Related]
55. Phantom study of the impact of reconstruction parameters on the detection of mini- and micro-volume lesions with a low-dose PET/CT acquisition protocol.
Ferretti A; Bellan E; Gava M; Chondrogiannis S; Massaro A; Nibale O; Rubello D
Eur J Radiol; 2012 Nov; 81(11):3363-70. PubMed ID: 22613508
[TBL] [Abstract][Full Text] [Related]
56. CT in PET/CT: essential features of interpretation.
Schöder H; Yeung HW; Larson SM
J Nucl Med; 2005 Aug; 46(8):1249-51. PubMed ID: 16085577
[No Abstract] [Full Text] [Related]
57. Body surface area adapted iopromide 300 mg/ml versus 370 mg/ml contrast medium injection protocol: influence on quantitative and clinical assessment in combined PET/CT.
Verburg FA; Apitzsch J; Lensing C; Kuhl CK; Pietsch H; Mottaghy FM; Behrendt FF
Eur J Radiol; 2013 Dec; 82(12):2348-52. PubMed ID: 24113432
[TBL] [Abstract][Full Text] [Related]
58. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
59. [Comparison of ¹⁸F-FDG PET/CT and large-scale DWI for evaluation of non-Hodgkin lymphoma bone marrow infiltration].
Tang R; Gui S; Li J; Zhang H; Lu B; Yang P; Fu D; Fu W; Li W; Cai L
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):231-5. PubMed ID: 24666490
[TBL] [Abstract][Full Text] [Related]
60. FDG PET/CT in cancer therapy monitoring: computer-assisted analysis of baseline together with up to two follow-ups.
Apostolova I; Renisch S; Opfer R; Derlin T; Buchert R; Carlsen IC; Brenner W
Nuklearmedizin; 2011; 50(2):83-92. PubMed ID: 21165536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
